{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:10:41Z","timestamp":1793391041701,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014489","name":"Johnson & Johnson Pharmaceutical Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jtha.2026.02.020","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:25:17Z","timestamp":1772641517000},"page":"2158-2169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rationale for the milvexian dosing in the phase 3 LIBREXIA program"],"prefix":"10.1016","volume":"24","author":[{"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.02.020_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.02.020_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ahj.2025.02.011","article-title":"Oral factor XIa inhibitor milvexian after a recent acute coronary syndrome: rationale and design of the phase 3 (Librexia ACS)","volume":"285","author":"Gibson","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2026.02.020_bib4","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2026.02.020_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.02.020_bib7","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3390\/jcm13072009","article-title":"Inappropriate underdosing of direct oral anticoagulants in atrial fibrillation patients: results from the START2-AF registry","volume":"13","author":"Poli","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.02.020_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","article-title":"Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry","volume":"128","author":"Mei","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/pds.5317","article-title":"Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies","volume":"30","author":"van den Ham","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2026.02.020_bib11","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/bloodadvances.2024013126","article-title":"More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study","volume":"8","author":"Palareti","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.02.020_bib12","first-page":"353","article-title":"New oral anticoagulants-TURKey (NOAC-TURK): multicenter cross-sectional study","volume":"17","author":"Altay","year":"2017","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.jtha.2026.02.020_bib13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.02.020_bib14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.02.020_bib15","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/jcm13082277","article-title":"Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation","volume":"13","author":"Gue","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42444-021-00053-9","article-title":"Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants","volume":"23","author":"Park","year":"2022","journal-title":"Int J Arrhythm"},{"key":"10.1016\/j.jtha.2026.02.020_bib17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10840-022-01274-1","article-title":"Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database","volume":"66","author":"Munir","year":"2023","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.jtha.2026.02.020_bib18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad302","article-title":"Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF","volume":"25","author":"Guenoun","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2026.02.020_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.hoc.2021.07.012","article-title":"Factor XI deficiency","volume":"35","author":"Lewandowska","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtha.2026.02.020_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019644","article-title":"Genetically proxied inhibition of coagulation factors and risk of cardiovascular disease: a Mendelian randomization study","volume":"10","author":"Yuan","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.02.020_bib22","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/STROKEAHA.118.022792","article-title":"Genetically determined FXI (factor XI) levels and risk of stroke","volume":"49","author":"Gill","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.02.020_bib23","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.02.020_bib24","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.02.020_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.020_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.020_bib27","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1055\/a-2061-3311","article-title":"Antithrombotic effects of the novel small-molecule factor XIa inhibitor milvexian in a rabbit arteriovenous shunt model of venous thrombosis","volume":"7","author":"Wang","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2026.02.020_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2026.02.020_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70058","article-title":"Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: an intravenous microtracer approach","volume":"17","author":"Jarugula","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2026.02.020_bib30","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40262-022-01150-1","article-title":"Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment","volume":"61","author":"Perera","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.02.020_bib31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/DDDT.S488414","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of milvexian in healthy Chinese adults","volume":"19","author":"Luo","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jtha.2026.02.020_bib32","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-022-08768-y","article-title":"Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants","volume":"12","author":"Perera","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2026.02.020_bib33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40119-022-00266-6","article-title":"Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a factor XIa inhibitor","volume":"11","author":"Perera","year":"2022","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jtha.2026.02.020_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102600","article-title":"The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in vitro","volume":"8","author":"Bunce","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.020_bib35","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.02.020_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/23969873221100032","article-title":"European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack","volume":"7","author":"Dawson","year":"2022","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.jtha.2026.02.020_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib40","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1161\/STROKEAHA.110.602615","article-title":"Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis","volume":"42","author":"Mohan","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.02.020_bib41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.02.020_bib42","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.02.020_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS trial","volume":"139","author":"Sharma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.02.020_bib44","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1161\/STROKEAHA.120.029762","article-title":"Rivaroxaban for prevention of covert brain infarcts and cognitive decline: the COMPASS MRI substudy","volume":"51","author":"Sharma","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.02.020_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67182-8","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and\/or clopidogrel in healthy participants","volume":"14","author":"Perera","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2026.02.020_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cpt.70037","article-title":"Quantitative model-informed dose selection for a milvexian phase 3 study in patients with atrial fibrillation","volume":"119","author":"Zhou","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2026.02.020_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2026.02.020_bib51","first-page":"649","article-title":"AF and venous thromboembolism - pathophysiology, risk assessment and CHADS-VASc score","volume":"5","author":"Shariff","year":"2012","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.jtha.2026.02.020_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib54","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.02.020_bib55","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.3390\/jcm12216909","article-title":"The left atrial appendage and atrial fibrillation-a contemporary review","volume":"12","author":"Sulague","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib56","article-title":"Leveraging Mendelian randomization to inform drug discovery and development for ischemic stroke","author":"Daghlas","year":"2024","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jtha.2026.02.020_bib57","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.V108.11.574.574","article-title":"A phase II randomized, double-blind, eight-arm, parallel-group, dose-response study of apixaban, a new oral factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery - on behalf of the Apixaban Investigators","volume":"108","author":"Lassen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.02.020_bib58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib59","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib60","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib61","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtha.2026.02.020_bib62","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.020_bib63","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtha.2026.02.020_bib64","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.02.020_bib65","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.02.020_bib67","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1055\/s-0040-1713376","article-title":"Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence","volume":"120","author":"Weitz","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.020_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.02.020_bib69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626001388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626001388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:06:55Z","timestamp":1780574815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1538783626001388"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.02.020","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for the milvexian dosing in the phase 3 LIBREXIA program","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}